Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract...
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16 sept. 2024 08h30 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
23 août 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark ...
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
16 août 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of themOutcome further confirms Bentrio’s...
Allergy Vaccine Market Trends, Forecast and Competitive Analysis: A $3.6 Billion Market by 2030 with a CAGR of 7.5% from 2024 to 2030
31 mai 2024 04h18 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Allergy Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
23 mai 2024 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and...
Allergy Immunotherapy Market revenue to cross USD 6 Billion by 2036, says Research Nester
01 févr. 2024 07h00 HE
|
Research Nester
New Yorke , Feb. 01, 2024 (GLOBE NEWSWIRE) -- The global allergy immunotherapy market size is estimated to attain at 10% CAGR from 2024 to 2036. The market is expected to garner a revenue of USD 6...
Nasal Allergy Treatment Market: Anticipating a Reach of US$ 21.4 Billion by 2032, Projected for Substantial Growth at a 4% CAGR from 2022 to 2032 | Persistence Market Research
10 janv. 2024 09h48 HE
|
Persistence Market Research
New Yor, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The global nasal allergy treatment market is poised for steady growth, driven by the increasing prevalence of allergic rhinitis, a chronic inflammatory...
Inhalation and Nasal Spray Market Worth USD 57.98 Billion in 2032 | Emergen Research
07 déc. 2023 09h02 HE
|
Emergen Research
Vancouver, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global Inhalation and Nasal Spray Market will be worth USD 57.98 billion by 2032, according to a current analysis by Emergen Research. An increasing...
Sublingual Allergy Immunotherapy Market Size to Surpass US$ 1.02 billion by 2033 at a CAGR of 9.1%| Persistence Market Research
12 juin 2023 09h45 HE
|
Persistence Market Research
New York, June 12, 2023 (GLOBE NEWSWIRE) -- The sublingual allergy immunotherapy (SLIT) market has been experiencing steady growth in recent years due to increasing prevalence of allergies and...